Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2012

View Archived Issues

Takeda Pharmaceutical offers overview of third quarter fiscal 2011

BiondVax's phase II flu vaccine trial meets primary safety endpoint

Debiopharm commences phase Ib expansion study of Debio-0932

Hanmi and AngioLab enter licensing agreement

Studies point to benefit of sonothrombolysis after stroke

New antiviral agents disclosed by Alla Chem

Alla Chem presents new androgen receptor antagonists

Latvian company patents novel agents for influenza

New protein kinase inhibitors synthesized by Chinese team

Trials indicate ipilimumab can be administered with cancer vaccines

Novel tissue engineering scaffolds tested in vivo

Hyundai Pharmaceutical discloses new GPR119 receptor agonists

Novartis to revise product information for Rasilez in the E.U.

GlaxoSmithKline provides regulatory update on Tykerb/Tyverb

NeuroPhage Pharmaceuticals receives funding from Michael J. Fox Foundation

GlaxoSmithKline receives CHMP opinion on Nimenrix

Collaborating Japanese universities identify new potential target for cancer therapy

Gilead Sciences reports on ELECTRON trial

New approval for Zelboraf

Dainippon Sumitomo seeks line extension for Amlodin in Japan

EMA committee recommends conditional approval of Pixuvri

TCG Lifesciences chooses preclinical development candidate

CHMP recommends approval of Byetta line extension

FDA approves first medical therapy for endogenous Cushing's syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...